

## MINI FOCUS ON DIABETES

### ORIGINAL INVESTIGATIONS

# Genetic Variants in *SGLT1*, Glucose Tolerance, and Cardiometabolic Risk



Sara B. Seidelmann, MD, PhD,<sup>a,b</sup> Elena Feofanova, MS,<sup>c</sup> Bing Yu, PhD,<sup>c</sup> Nora Franceschini, MD,<sup>d</sup> Brian Claggett, PhD,<sup>a</sup> Mikko Kuokkanen, PhD,<sup>e,f</sup> Hannu Puolijoki, MD, PhD,<sup>g</sup> Tapani Ebeling, MD, PhD,<sup>h</sup> Markus Perola, MD, PhD,<sup>e,f</sup> Veikko Salomaa, MD, PhD,<sup>e</sup> Amil Shah, MD,<sup>a</sup> Josef Coresh, MD, PhD,<sup>i</sup> Elizabeth Selvin, PhD, MPH,<sup>i</sup> Calum A. MacRae, MD, PhD,<sup>a</sup> Susan Cheng, MD,<sup>a</sup> Eric Boerwinkle, PhD,<sup>c,j</sup> Scott D. Solomon, MD<sup>a</sup>

#### ABSTRACT

**BACKGROUND** Loss-of-function mutations in the *SGLT1* (sodium/glucose co-transporter-1) gene result in a rare glucose/galactose malabsorption disorder and neonatal death if untreated. In the general population, variants related to intestinal glucose absorption remain uncharacterized.

**OBJECTIVES** The goal of this study was to identify functional *SGLT1* gene variants and characterize their clinical consequences.

**METHODS** Whole exome sequencing was performed in the ARIC (Atherosclerosis Risk in Communities) study participants enrolled from 4 U.S. communities. The association of functional, nonsynonymous substitutions in *SGLT1* with 2-h oral glucose tolerance test results was determined. Variants related to impaired glucose tolerance were studied, and Mendelian randomization analysis of cardiometabolic outcomes was performed.

**RESULTS** Among 5,687 European-American subjects (mean age  $54 \pm 6$  years; 47% male), those who carried a haplotype of 3 missense mutations (frequency of 6.7%)—Asn51Ser, Ala411Thr, and His615Gln—had lower 2-h glucose and odds of impaired glucose tolerance than noncarriers ( $\beta$ -coefficient:  $-8.0$ ; 95% confidence interval [CI]:  $-12.7$  to  $-3.3$ ; OR: 0.71; 95% CI: 0.59 to 0.86, respectively). The association of the haplotype with oral glucose tolerance test results was consistent in a replication sample of 2,791 African-American subjects ( $\beta = -16.3$ ; 95% CI:  $-36.6$  to 4.1; OR: 0.39; 95% CI: 0.17 to 0.91) and an external European-Finnish population sample of 6,784 subjects ( $\beta = -3.2$ ; 95% CI:  $-6.4$  to  $-0.02$ ; OR: 0.81; 95% CI: 0.68 to 0.98). Using a Mendelian randomization approach in the index cohort, the estimated 25-year effect of a reduction of 20 mg/dl in 2-h glucose via *SGLT1* inhibition would be reduced prevalent obesity (OR: 0.43; 95% CI: 0.23 to 0.63), incident diabetes (hazard ratio [HR]: 0.58; 95% CI: 0.35 to 0.81), heart failure (HR: 0.53; 95% CI: 0.24 to 0.83), and death (HR: 0.66; 95% CI: 0.42 to 0.90).

**CONCLUSIONS** Functionally damaging missense variants in *SGLT1* protect from diet-induced hyperglycemia in multiple populations. Reduced intestinal glucose uptake may protect from long-term cardiometabolic outcomes, providing support for therapies that target *SGLT1* function to prevent and treat metabolic conditions. (J Am Coll Cardiol 2018;72:1763-73)

© 2018 Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



Listen to this manuscript's audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.



From the <sup>a</sup>Cardiovascular Division and <sup>b</sup>Division of Cardiovascular Imaging, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts; <sup>c</sup>Epidemiology, Human Genetics & Environmental Sciences, UTHealth School of Public Health, Houston, Texas; <sup>d</sup>Department of Epidemiology, UNC Gillings Global School of Public Health, Chapel Hill, North Carolina; <sup>e</sup>National Institute for Health and Welfare, Helsinki, Finland; <sup>f</sup>University of Helsinki, Diabetes and Obesity Research Program, Helsinki, Finland; <sup>g</sup>South Ostrobothnia Hospital District, Seinäjoki, Finland; <sup>h</sup>Department of Medicine, Oulu University Hospital and University of Oulu, Oulu, Finland; <sup>i</sup>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, and Welch Center for Prevention, Epidemiology, and Clinical Research and Division of General Internal Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland; and the <sup>j</sup>Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas. The ARIC study is performed as a collaborative study supported by National Heart, Lung, and Blood Institute

## ABBREVIATIONS AND ACRONYMS

<b>BP</b>	= blood pressure
<b>CI</b>	= confidence interval
<b>DM</b>	= diabetes mellitus
<b>FFQ</b>	= food frequency questionnaire
<b>GGM</b>	= glucose-galactose malabsorption
<b>GLP</b>	= glucagon-like peptide
<b>HF</b>	= heart failure
<b>HGSC</b>	= Human Genome Sequencing Center
<b>ICD</b>	= International Statistical Classification of Diseases and Related Health Problems
<b>IGT</b>	= impaired glucose tolerance
<b>NS</b>	= nonsynonymous
<b>OGTT</b>	= oral glucose tolerance test
<b>OR</b>	= odds ratio
<b>SGLT</b>	= sodium/glucose co-transporter

After ingestion, complex carbohydrates are enzymatically broken down to produce monosaccharides (glucose, galactose, and fructose), which are absorbed in the small intestine and used as substrate for the body's metabolically active tissues. The sodium/glucose co-transporter (*SGLT*)-1 protein is a rate-limiting factor for absorption of glucose and galactose in the small intestine, and it uses transmembrane sodium gradients to drive the cellular uptake of these molecules. Loss-of-function mutations, including missense, nonsense, and frameshift mutations, of the *SGLT1* gene result in impaired cellular glucose transport and cause glucose-galactose malabsorption (GGM). GGM is a rare, autosomal recessive, Mendelian disorder resulting in neonatal onset of severe diarrhea, dehydration, and malabsorption (1-3).

SEE PAGE 1774

Functional gene variants in *SGLT1* associated with altered glucose metabolism in the general population have not been described. However, in the process of identifying causal mutations for GGM, *SGLT1* gene variants that are associated with subtle abnormalities of glucose absorption *in vivo* have been identified; the importance of these variants, which do not result in GGM, is unknown (1). We hypothesized that rare or low-frequency variants in *SGLT1* that are predicted to be damaging, but still preserve some of the protein's function, result in lower postprandial blood glucose levels by decreasing glucose uptake in the small

intestine and thereby reduce overall caloric absorption. Rare or low-frequency variant analysis of *SGLT1* has not been systematically studied in the general population and could provide insights into the gene's relationship with diet and disease, as well as potential drug targets for hyperglycemia and obesity and its consequences. We assessed the relationship between protein-altering, nonsynonymous (NS) substitutions in *SGLT1* and glycemia and obesity by using whole exome sequencing performed in participants from 4 U.S. communities who were enrolled in the ARIC (Atherosclerosis Risk In Communities) study. External validation was then performed in a European-Finnish population sample (FINRISK and DILGOM [Dietary, Lifestyle and Genetic Predictors of Obesity and Metabolic Syndrome] study). A Mendelian randomization approach was then used to estimate the effect of *SGLT1* inhibition on long-term cardiometabolic outcomes.

## METHODS

**STUDY DESIGN AND STUDY POPULATION.** Originally comprising 15,792 men and women aged between 45 and 64 years, the ARIC study is an ongoing, prospective observational trial of atherosclerosis risk factors in 4 U.S. communities (Forsyth County, North Carolina; Jackson, Mississippi; suburbs of Minneapolis, Minnesota; and Washington County, Maryland) recruited between 1987 and 1989 (visit 1) (4). ARIC study participants were initially examined every 3 years, with the second examination occurring in the years 1990 to 1992, the third in 1993 to 1995, the fourth in 1996 to 1998, and the fifth in 2011 to 2013. At each participating site, institutional review boards

contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). Dr. Seidelmann was supported by National Institutes of Health (NIH) grant number 2T32HL094301-06. Dr. Salomaa was supported by the Finnish Foundation for Cardiovascular Research. Dr. Perola has received support from the EU FP7 under grant agreements nr. 313010 (BBMRI-LPC), nr. 305280, and H22020 633589 (Ageing with Elegans); The Finnish Academy grant no. 269517; and from the Yrjö Jahnsson Foundation. Dr. Kuokkanen was supported by the Päivikki and Sakari Sohlberg Foundation. Dr. Selvin was supported by NIH/National Institute of Diabetes and Digestive and Kidney Diseases grants K24DK106414 and R01DK089174. Dr. Cheng was supported by NIH grants R01HL131532 and R01HL134168. There was no direct role of any funder in the design, collection, analysis, or interpretation of the data, nor in the preparation, review, or approval of the manuscript. Dr. Claggett has consulted for Corvia, Gilead, AOBiome, and Boehringer Ingelheim. Dr. Shah has received research funding from Novartis and Bellerophon; and has consulted for Philips Ultrasound, Bellerophon, and GlaxoSmithKline. Dr. Cheng has consulted for Novartis and Zogenix. Dr. MacRae has received research funding from the American Heart Association, Verily, AstraZeneca Merck, Sanofi, and Novartis. Dr. Boerwinkle has served as a scientific officer for Codified Genomics, LLC. Dr. Solomon has received research grants from Alnylam, Amgen, AstraZeneca, Bellerophon, Bristol-Myers Squibb, Celladon, Gilead, GlaxoSmithKline, Ionis, Lone Star Heart, Mesoblast, MyoKardia, NIH/National Heart, Lung, and Blood Institute, Novartis, Sanofi Pasteur, Theracos; and has consulted for Alnylam, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Corvia, Gilead, GlaxoSmithKline, Ironwood, Merck, Novartis, Pfizer, Takeda, and Theracos. These relationships did not fund the current study. Dr. Salomaa has participated in a conference trip sponsored by Novo Nordisk. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Manuscript received May 25, 2018; revised manuscript received July 11, 2018, accepted July 15, 2018.

approved the study protocol. Informed consent was obtained in writing at each study visit. Participants were excluded from this analysis if they restricted use of their deoxyribonucleic acid (DNA) ( $n = 44$ ).

**MEASUREMENT OF DIET.** At the baseline visit (1987 to 1989), participants were interviewed by using a 66-item semi-quantitative food frequency questionnaire (FFQ), modified from a 61-item validated FFQ (5). Participants reported the occurrence with which they consumed individual foods or beverages in 9 categories (ranging from never or <1 time per month to  $\geq 6$  times per day). Nutrient intakes were derived from FFQ responses using the Harvard Nutrient Database.

**PHENOTYPIC MEASUREMENTS.** Age, sex, race (self-reported), total cholesterol (measured by using blood plasma assay), high-density lipoprotein (measured by blood plasma assay), current smoking status (self-reported), hypertension (HTN) (defined as +antihypertensive medications or blood pressure  $>140/90$  mm Hg), estimated glomerular filtration rate, chronic kidney disease (defined as an estimated glomerular filtration rate  $<60$  ml/min/1.73 m<sup>2</sup>), and obesity (defined as a body mass index  $\geq 30$  kg/m<sup>2</sup>) were analyzed at baseline visit. Baseline systolic blood pressure was adjusted for +15 mm Hg and diastolic blood pressure +10 mm Hg if the subject was taking antihypertensive medication (assessed by self-reported questionnaire). A standard 75-g oral glucose tolerance test (OGTT) was performed after an overnight fast before ARIC visit 4 (1996 to 1998). Participants who were taking diabetes mellitus (DM) medications at visit 4, had a recent history of taking DM medications (at visit 3), reported not fasting for at least 12 h, or had had part of their stomach removed did not qualify to undergo OGTT. Impaired glucose tolerance (IGT) was defined as a 2-h postprandial glucose level  $\geq 140$  mg/dl to associate all individuals with potentially abnormal physiological handling of glucose to gene variants of interest. All participants who underwent OGTT were included in the current analysis.

Sensitivity analyses were performed excluding individuals with a diagnosis of DM or with a fasting plasma glucose level  $>126$  mg/dl. All analytes were determined at central laboratories according to standard protocols. Plasma glucose was measured by using a hexokinase assay.

**OUTCOMES.** Outcomes evaluated in this study are incident DM diagnosis, initiation of DM medications, death, and incident heart failure (HF), from the first visit until 2015 (median 25-year follow-up). Because heritable functional variations in *SGLT1* could

theoretically influence an individual's success in the dietary management of DM, a diagnosis of DM and initiation of DM medications were explored separately as outcomes. Patients at risk of HF are also at risk of cardiovascular death before development of overt HF; thus, both the individual outcomes as well as a composite of the first occurrence of HF or death was assessed. The methods used for the detection and adjudication of events have been presented previously (6-8). Incident death was determined via death certificates, hospitalized patients, physician questionnaires, and next-of-kin interviews. Incident HF was defined as the first HF hospitalization identified by International Statistical Classification of Diseases and Related Health Problems (ICD) codes 428 (for ICD-9) or I50 (for ICD-10) in any position on hospital discharge or deaths coded as HF (428 or I50) in any position on death certificates (8). Incident cases of DM were identified based on self-reported DM diagnosis or use of DM medications during the scheduled ARIC visits as well as annual telephone interviews conducted with participants for a maximum of 15 years of follow-up (7).

**WHOLE EXOME SEQUENCING.** Whole exome sequencing was performed at the Baylor College of Medicine Human Genome Sequencing Center (HGSC), using the HGSC VCRome 2.1 reagent (9) (42 Mb, NimbleGen). All samples underwent paired-end sequencing by using GAII or HiSeq instruments (Illumina, San Diego, California). Atlas2 suite was used to perform the variant calling (10). The DNA samples were constructed into Illumina paired-end pre-capture libraries according to the manufacturer's protocol. The complete protocol and oligonucleotide sequences are accessible from the Baylor College of Medicine-HGSC website. Barcoded pre-capture libraries were pooled and then hybridized to NimbleGen exome capture array (HGSC VCRome 2.1 design [9]) (42 Mb, NimbleGen) and sequenced in paired-end mode in a single lane on the Illumina HiSeq 2000 platform. Illumina sequence analysis was performed by using the HGSC Mercury analysis pipeline. Pooled samples were de-multiplexed by using Consensus Assessment of Sequence and Variation software (Illumina). Reads were then mapped to the Genome Reference Consortium Human Build 37 human reference sequence using Burrows-Wheeler Aligner (11) producing binary alignment/map files. Aligned reads were then recalibrated by using the Genome Analysis Toolkit (12) along with binary alignment/map sorting, duplicate read marking, and realignment near insertions or deletions. The Atlas2 (10) suite was used to call variants and produce high-quality variant call files (13).

Each single nucleotide variant call was filtered based on the following criteria to produce a high-quality variant list: low single nucleotide variant posterior probability ( $<0.95$ ), low variant read count ( $<3$ ), variant read ratio  $<0.25$  or  $>0.75$ , strand-bias of  $>99\%$  variant reads in a single strand direction, or total coverage  $<10$ -fold. All variant calls filtered according to these criteria, and reference calls with  $<10$ -fold coverage, were set to missing. The variant call filters were the same for insertions or deletions except a total coverage  $<30$ -fold was used. Variant-level quality control steps excluded variants outside the exon capture regions (VChrom 2.1), multi-allelic sites, missing rate  $>20\%$ , and mean depth of coverage  $>500$ -fold. Variants not meeting Hardy-Weinberg equilibrium expectations in ancestry-specific groups ( $p < 5 \times 10^{-6}$ ) were also excluded. Sample-level quality control metrics were calculated according to cohort and ancestry group. A sample was excluded for missingness  $>20\%$ , or, if compared with the other samples, it fell  $<6$  SDs for mean depth,  $>6$  SDs for singleton count, or outside of 6 SDs for heterozygote to homozygote ratio or a transition-to-transversion ratio. We selected all NS variants in the *SGLT1* gene for this study. Protein function was determined from previous in vivo studies of heterologous expression that determined glucose uptake in cells expressing *SGLT1* mutant proteins (1).

**EXTERNAL VALIDATION COHORTS.** FINRISK is a series of cardiovascular risk factor surveys conducted in Finland every 5 years since 1972 (14). DNA has been collected since the 1992 survey. The FINRISK 2002 study is a stratified, random sample of the population 25 to 74 years of age from 6 geographical areas of Finland (15). The original population sample was 13,500, and the overall participation rate was 65.5% ( $n = 8,798$ ). Participation included a questionnaire and health examination in which blood samples were drawn. Testing for OGTT with fasting and 2-h glucose assessment was conducted in a separate session for participants 45 to 74 years of age ( $n = 3,738$ ) approximately 2 months after the baseline survey.

The DILGOM study is an extension of the FINRISK 2007 survey and is based on an independent population sample, separate from FINRISK 2002 (16). All participants of FINRISK 2007 were further invited to take part in a more detailed study (i.e., DILGOM). The participation rate was 80% ( $n = 5,024$ ). The baseline examination of DILGOM in 2007 was conducted about 3 months after the original FINRISK 2007 survey. It included a 2-h OGTT with measurements of fasting and 2-h glucose assessment.

Of the FINRISK and DILGOM participants with OGTT, a total of 6,784 had data on IGT and 2-h glucose assessments available for the present analysis. The analysis on prevalent obesity included FINRISK-92, -97, -02, -07, and -12 cohorts (total  $N = 27,294$ ). All analyses were performed by using directly genotyped or 1,000 Genomes phase 3 imputed data (quality  $>0.99$ ).

**STATISTICAL ANALYSIS.** Baseline characteristics are reported by using descriptive statistics for continuous variables and number counts and percentages for categorical variables. Linear regression and chi-square tests for trend were used to test for a relationship between continuous or categorical baseline variables, respectively, and *SGLT1* genotype. All analyses were adjusted for age at the time that the measurement was obtained, sex, and, in a combined analysis, the first 10 principal components from EIGENSTRAT (17) to minimize confounding by ancestry. Genotype-phenotype associations were first examined in a sample of European-American subjects with exome sequencing genotypes and then replicated in African-American subjects. To estimate the contribution of an individual missense mutation to the overall NS variant signal, conditional analyses were performed. These evaluated the association of all NS variants with IGT, further adjusting for each individual missense mutation as a covariate. Survival analysis methods were used for the following outcomes: diagnosis of DM, initiation of DM medications, death, and HF. Follow-up time was calculated as the time from the first examination to the time of the first event or the last known date of follow-up (up to December 31, 2014).

Kaplan-Meier failure curves were created for each outcome, and hazard ratios (HRs) were calculated by using Cox proportional hazards regression. These analyses were first tested in an unadjusted model and then adjusted for age, sex, and the first 10 principal components from EIGENSTRAT (17) to minimize confounding by ancestry. The causal effects of reduced 2-h glucose values on outcomes and quantitative traits were examined according to conventional Mendelian randomization (2-stage least-squares estimator method), which uses predicted values of 2-h glucose per genotype and regresses each outcome or trait against these predicted values. Models were tested for each outcome variable and were adjusted for age, sex, and the first 10 principal components. All data were analyzed by using STATA version 14.0 (StataCorp, College Station, Texas). Values of  $p < 0.05$  were considered statistically significant.

**TABLE 1** Baseline Characteristics of European-American and African-American Participants in the ARIC Cohort Stratified According to the Presence of 1 or ≥2 NS Substitutions in SGLT1

	European-American Subjects				African-American Subjects			
	Control (NS = 0)	SGLT1 (NS = 1)	SGLT1 (NS ≥ 2)	p Value for Trend	Control (NS = 0)	SGLT1 (NS = 1)	SGLT1 (NS ≥ 2)	p Value for Trend
Patients	4,772 (84)	105 (2)	810 (14)		2,583 (92.5)	124 (4.5)	84 (3)	
Age, yrs	54 ± 6	54 ± 6	54 ± 6	0.83	53 ± 6	54 ± 6	54 ± 6	0.03
Male	2,268 (48)	44 (42)	385 (48)	0.88	933 (36)	46 (37)	30 (36)	0.97
Smoking	1,174 (25)	18 (17)	187 (23)	0.25	724 (28)	41 (33)	28 (33)	0.13
Current EtOH	3,262 (68)	80 (76)	561 (69)	0.44	794 (31)	45 (37)	30 (36)	0.15
TC, mg/dl	215 ± 39	216 ± 35	215 ± 38	0.95	213 ± 41	215 ± 51	214 ± 39	0.52
HDL, mg/dl	51 ± 17	54 ± 18	51 ± 17	0.42	55 ± 18	54 ± 17	56 ± 18	0.97
LDL, mg/dl	137 ± 36	138 ± 33	138 ± 35	0.71	136 ± 38	138 ± 46	137 ± 36	0.58
Triglycerides, mg/dl	139 ± 98	129 ± 118	132 ± 87	0.07	112 ± 85	116 ± 61	115 ± 67	0.59
SBP, mm Hg	122.1 ± 19.0	120.7 ± 18.3	120.8 ± 18.7	0.06	133.4 ± 21.2	133.7 ± 23.1	135.7 ± 25.8	0.37
DBP, mm Hg	74.2 ± 11.3	73.8 ± 10.8	73.3 ± 11.1	0.028	83.6 ± 12.9	84.2 ± 15.6	81.3 ± 15.1	0.29
Antihypertensive medication	1,200 (25)	45 (26)	156 (21)	0.029	1,080 (42)	52 (42)	41 (49)	0.23
HTN	1,262 (26)	46 (27)	164 (22)	0.021	1,363 (53)	68 (55)	47 (56)	0.45
Uric acid, mg/dl	5.17 ± 1.52	5.11 ± 1.60	4.96 ± 1.39	<0.001	5.43 ± 1.63	5.73 ± 1.67	5.47 ± 2.07	0.26
eGFR	89.3 ± 17.9	88.5 ± 18.6	88.9 ± 16.6	0.46	103.4 ± 26.4	101.8 ± 25.2	109.9 ± 29.5	0.13
CKD	145 (3.0)	4 (2.3)	16 (2.2)	0.17	55 (2.2)	4 (3.3)	0 (0.0)	0.47
Heart rate, beats/min	66.5 ± 10.0	64.9 ± 9.9	65.5 ± 9.4	0.005	66.8 ± 10.8	67.6 ± 12.1	65.1 ± 10.1	0.43
Total energy intake, kcal	1,644 ± 602	1,553 ± 498	1,623 ± 597	0.28	1,580 ± 614	1,696 ± 642	1,515 ± 568	0.85
Sodium intake, mg	1,513 ± 601	1,529 ± 611	1,553 ± 639	0.08	1,354 ± 544	1,428 ± 536	1,303 ± 571	0.99
Sucrose intake, g	51 ± 36	43 ± 25	49 ± 33	0.05	58 ± 37	65 ± 45	58 ± 37	0.30
Glucose intake, g	22 ± 14	20 ± 11	22 ± 14	0.63	24 ± 16	27 ± 17	24 ± 13	0.65
Fructose intake, g	24 ± 17	21 ± 12	24 ± 16	1.00	27 ± 18	30 ± 21	26 ± 16	0.72
Lactose intake, g	14 ± 13	14 ± 11	16 ± 14	0.04	10 ± 10	9 ± 8	9 ± 8	0.41

Values are n (%) or mean ± SD.  
ARIC = Atherosclerosis Risk In Communities Study; CKD = chronic kidney disease (defined as estimated glomerular filtration rate <60 ml/min/1.73 m<sup>2</sup>); DBP = diastolic blood pressure (adjusted for the use of antihypertensive medication); eGFR = estimated glomerular filtration rate; EtOH = alcohol; HDL = high-density lipoprotein cholesterol; HTN = hypertension (defined as +antihypertensive medications or blood pressure >140/90 mm Hg); LDL = low-density lipoprotein cholesterol; NS = nonsynonymous; SBP = systolic blood pressure (adjusted for the use of antihypertensive medication); SGLT1 = sodium/glucose co-transporter-1; TC = total cholesterol.


## RESULTS

Whole exome sequencing was performed in 8,478 participants in the ARIC cohort; 5,687 were European American and 2,791 were African American. A total of 915 (16%) European-American subjects and 208 (7.5%) African-American subjects carried at least 1 NS substitution in SGLT1 (Table 1, Online Table 1). Overall, baseline characteristics of the study population were similar between those who carried at least 1 NS substitution and those who did not. However, in European-American subjects, diastolic blood pressure, use of antihypertensive medications, prevalent HTN, uric acid levels, and heart rate were lower in those who carried at least 1 NS substitution in SGLT1. The mean number of NS substitutions in European-American and African-American subjects was 0.4 and 0.1, respectively.

We first tested whether overall NS variants were associated with phenotypes most likely to be correlated with SGLT1 function in ARIC European-American subjects, given its larger size. Carrying

one or more copies of an NS variant was associated with lower fasting and postprandial plasma glucose levels, lower risk of IGT, and obesity in European-American subjects (Online Table 2). Next, to identify specific NS variants that may have contributed to the overall NS substitution results, we tested the relationship of individual variants with IGT, which was the strongest detected association. All participants who underwent OGTT were included to study potentially abnormal physiological handling of glucose in SGLT1 variants. Sensitivity analyses excluding individuals with a DM diagnosis or those with fasting plasma glucose levels >126 mg/dl yielded similar results. Three variants (N51S, A411T, and H615Q) were significantly associated with a 25% to 27% reduction in IGT (odds ratio [OR]: 0.73, 0.72, and 0.75, respectively) (Central Illustration, Table 2). These variants were in high linkage disequilibrium, comprising a risk haplotype with a minor allele frequency of 6.7% (Online Table 3). Conditional analysis showed that the association of NS substitutions with IGT was completely explained by the

**CENTRAL ILLUSTRATION** Phenotype of Participants in the ARIC Study Cohort According to SGLT1 Asn51Ser/Ala411Thr/His615Gln Haplotype Carrier Status



Seidelmann, S.B. et al. J Am Coll Cardiol. 2018;72(15):1763-73.

Whole exome sequencing of *Sglt1* was performed in ARIC (Atherosclerosis Risk in Communities) study participants enrolled from 4 U.S. communities. Among 5,687 European-American subjects (mean age 54 ± 6 years), those who carried a haplotype of 3 missense mutations (Asn51Ser, Ala411Thr, and His615Gln) had lower 2-h glucose and odds of impaired glucose tolerance than noncarriers. The association of the haplotype with oral glucose tolerance test results was consistent in a replication sample of 2,791 African-American subjects and an external European-Finnish population sample of 6,784. Using a Mendelian randomization approach in the index cohort, we estimated the 25-year effect of a 20 mg/dl reduction in 2-h glucose via sodium/glucose cotransporter-1 (SGLT1) inhibition on prevalent obesity, incident diabetes, heart failure, and death. DILGOM = Dietary, Lifestyle and Genetic Predictors of Obesity and Metabolic Syndrome.

**TABLE 2** List of NS Variants From Exome Sequencing of SGLT1 in ARIC European-American and African-American Subjects

Allele Count	Chrom	Position	RSID	Ref	Alt	Amino Acid Change	Transcript Consequence	CADD Raw	CADD Phred	Association of Single Variant With IGT* OR (95% CI)	Conditional Analysis†
European-American subjects (n = 5,687)											
834	22	32506050	rs33954001	C	G	p.His615Gln	c.1845C>G	0.74	11.22	0.75 (0.63-0.90)	0.69 (0.52-0.93)
829	22	32445946	rs17683011	A	G	p.Asn51Ser	c.152A>G	1.23	14.55	0.73 (0.61-0.87)	0.81 (0.59-1.11)
773	22	32487700	rs17683430	G	A	p.Ala411Thr	c.1231G>A	2.94	22.80	0.72 (0.60-0.87)	0.77 (0.54-1.09)
23	22	32479102	rs150117594	G	T	p.Val209Leu	c.625G>T	0.76	11.39	1.00 (0.38-2.62)	0.83 (0.75-0.92)
19	22	32506051	rs61733910	G	A	p.Gly616Ser	c.1846G>A	1.14	13.97	1.07 (0.38-3.08)	0.83 (0.75-0.92)
10	22	32439318	rs33951240	T	C	p.Val17Ala	c.50T>C	0.17	5.82	1.00 (0.17-6.04)	0.83 (0.75-0.92)
7	22	32439303	rs150288967	C	T	p.Ala12Val	c.35C>T	0.41	8.63	1.57 (0.31-7.96)	0.83 (0.75-0.92)
4	22	32505988	rs147453689	C	A	p.Pro595Thr	c.1783C>A	0.80	11.66	4.78 (0.49-46.3)	0.83 (0.75-0.92)
3	22	32439369	rs139760182	T	C	p.Ile34Thr	c.101T>C				
3	22	32482251	rs141412905	G	A	p.Gly356Ser	c.1066G>A				
2	22	32439357	.	C	T	p.Ser30Phe	c.89C>T				
2	22	32479100	.	C	T	p.Thr208Met	c.623C>T				
2	22	32480470	.	A	C	p.Met237Leu	c.709A>C				
2	22	32481013	.	C	G	p.Leu338Val	c.1012C>G				
2	22	32500780	.	G	A	p.Arg558His	c.1673G>A				
African-American subjects (n = 2,791)											
110	22	32439318	rs33951240	T	C	p.Val17Ala	c.50T>C	0.17	5.82	1.24 (0.62-2.50)	0.62 (0.41-0.95)
84	22	32445946	rs17683011	A	G	p.Asn51Ser	c.152A>G	1.23	14.55	0.39 (0.17-0.91)	1.13 (0.58-2.17)
82	22	32487700	rs17683430	G	A	p.Ala411Thr	c.1231G>A	2.94	22.8	0.39 (0.17-0.91)	1.13 (0.58-2.17)
82	22	32506050	rs33954001	C	G	p.His615Gln	c.1845C>G	0.74	11.22	0.40 (0.17-0.91)	1.13 (0.59-2.18)
5	22	32506051	rs61733910	G	A	p.Gly616Ser	c.1846G>A	1.14	13.97	0	0.73 (0.52-1.04)
2	22	32439338	rs201800716	C	T	p.Arg24Cys		1.64	16.68		

24 additional variants in European-American subjects and 15 additional variants in African-American subjects only represented in a single individual are not listed. \*Adjusted for age and sex. †Conditional analysis tests the association of all NS variants with impaired glucose tolerance (IGT) on oral glucose tolerance test adjusting for each individual mutation as a covariate. This estimates the contribution of the individual mutation in the overall NS signal. IGT was defined as 2-h glucose level  $\geq 140$  mg/dL.

Alt = alternate nucleic acid; CADD = Combined Annotation Dependent Depletion; Chrom = chromosome; CI = confidence interval; OR = odds ratio; Ref = reference nucleic acid; other abbreviations as in Table 1.

N51S/A411T/H615Q haplotype, suggesting that this haplotype was responsible for the original NS signal. Complete characterization of the N51S/A411T/H615Q haplotype in ARIC European-American subjects revealed a significant association with lower levels of postprandial glucose ( $\beta = -8.0$ ; 95% confidence interval [CI]:  $-12.7$  to  $-3.3$ ), risk for IGT (OR: 0.71; 95% CI: 0.59 to 0.86), and prevalent obesity (OR: 0.79; 95% CI: 0.66 to 0.96) (Table 3). To further validate our primary findings, we examined the associations with OGTT phenotypes in an independent sample of individuals of European ancestry living in Finland and participating in the FINRISK and DILGOM studies (mean age  $54 \pm 12$  years; body mass index  $27.4 \pm 4.8$  kg/m<sup>2</sup>; 47% male). The SGLT1 haplotype (minor allele frequency of 5.6%) was significantly associated with lower 2-h glucose values ( $\beta = -3.2$ ; 95% CI:  $-6.4$  to  $-0.02$ ) and IGT (OR: 0.80; 95% CI: 0.74 to 0.91), and displayed a directionally consistent relationship with obesity in this sample.

We further tested the association of the N51S/A411T/H615Q haplotype with OGTT and obesity in ARIC African-American subjects (minor allele

frequency of 1.5%) (Online Table 3). The haplotype was significantly associated with lower risk of IGT (OR: 0.39; 95% CI: 0.17 to 0.91) and obesity (OR: 0.60; 95% CI: 0.37 to 0.98) and a trend for 2-h glucose values ( $\beta = -16.3$ ; 95% CI:  $-36.6$  to 4.1) in that population (Central Illustration, Table 3). A combined analysis included ARIC European-American subjects, ARIC African-American subjects, and FINRISK/DILGOM European Finnish subjects with additional adjustment for principal components as covariates to minimize confounding by ancestry. The N51S/A411T/H615Q haplotype was significantly associated with 2-h glucose levels ( $\beta = -4.9$ ; 95% CI:  $-7.5$  to  $-2.3$ ;  $p = 2.4 \times 10^{-4}$ ), lower risk for IGT (OR: 0.75; 95% CI: 0.66 to 0.85;  $p = 1.1 \times 10^{-5}$ ) as well as prevalent obesity (OR: 0.80; 95% CI: 0.70 to 0.93;  $p = 2.5 \times 10^{-3}$ ) without a significant effect on fasting plasma glucose values (Table 3). The association of IGT and haplotype remained significant after including obesity as a covariate in the ARIC populations (OR: 0.74; 95% CI: 0.61 to 0.90).

To test the association of the N51S/A411T/H615Q haplotype with disease phenotypes that may be

**TABLE 3 OGTT Results and Prevalent Obesity in Participants in the ARIC and FINRISK/DILGOM Cohorts Stratified According to the Asn51Ser/Ala411Thr/His615Gln Haplotype in SGLT1**

	OGTT			
	Fasting Glucose Value, mg/dl (Beta-Coefficients)	2-h Glucose Value, mg/dl (Beta-Coefficients)	IGT OR (95% CI)	Obesity OR (95% CI)
European-American subjects (n = 5,687)	-2.7 (-5.1 to -0.3)	-8.0 (-12.7 to -3.3)	0.71 (0.59 to 0.86)	0.79 (0.66 to 0.96)
p value*	0.16	$9.4 \times 10^{-4}$	$3.2 \times 10^{-4}$	0.017
African-American subjects (n = 2,791)	-4.3 (-19.7 to 11.1)	-16.3 (-36.6 to 4.1)	0.39 (0.17 to 0.91)	0.60 (0.37 to 0.98)
p value*	0.58	0.12	0.03	0.040
FINRISK/DILGOM (n = 6,784)†	-0.3 (-1.5 to 1.1)	-3.2 (-6.4 to -0.02)	0.81 (0.68 to 0.98)	0.89 (0.71 to 1.12)
p value‡	0.66	0.05	0.03	0.38
Meta-analysis	-0.83 (-2.0 to 0.3)	-4.9 (-7.5 to -2.3)	0.75 (0.66 to 0.85)	0.80 (0.70 to 0.93)
p value‡	0.16	$2.4 \times 10^{-4}$	$1.1 \times 10^{-5}$	$2.5 \times 10^{-3}$

Oral glucose tolerance test (OGTT) was performed at ARIC examination 4; IGT was defined as 2-h glucose  $\geq 140$  mg/dl. \*Adjusted for age and sex. †For prevalent obesity, FINRISK/DILGOM (Dietary, Lifestyle and Genetic Predictors of Obesity and Metabolic Syndrome), n = 27,294. ‡Adjusted for age and sex, with additional adjustment for the first 5 (FINRISK/DILGOM) or 10 (ARIC) principal components as covariates to minimize confounding by ancestry.  
Other abbreviations as in Tables 1 and 2.

affected by alteration of the gene’s function, we focused on long-term clinical outcomes using the combined ARIC European- and African-American samples. After a 25-year median follow-up, there were 1,943 incident cases of DM, 1,556 incident HF events, and 3,319 deaths. The N51S/A411T/H615Q haplotype was significantly associated with a reduced incidence of diagnosis of DM and initiation of DM medications in unadjusted models (HR: 0.77 [95% CI: 0.66 to 0.89],  $p = 3.8 \times 10^{-4}$ ; HR: 0.72 [95% CI: 0.61 to 0.85],  $p = 6.7 \times 10^{-5}$ , respectively) and in age-, sex-, and principal component-adjusted models (HR: 0.81 [95% CI: 0.69 to 0.94],  $p = 0.006$ ; HR: 0.78 [95% CI: 0.66 to 0.92],  $p = 0.004$ ) (Online Figure 1). This haplotype was also associated with reduced risk of death or HF (HR: 0.80; 95% CI: 0.71 to 0.90;  $p = 2.5 \times 10^{-4}$ ) in the combined ARIC sample, after adjustment for age, sex, and principal components ( $p = 8.9 \times 10^{-4}$ ). This finding was also observed when assessing the outcomes of HF and death separately in both unadjusted models (HR: 0.71 [95% CI: 0.58 to 0.87],  $p = 6.4 \times 10^{-4}$ ; HR: 0.81 [95% CI: 0.71 to 0.93],  $p = 0.0018$ ) and adjusted models (HR: 0.74

[95% CI: 0.60 to 0.91],  $p = 0.0046$ ; HR: 0.81 [95% CI: 0.71 to 0.94],  $p = 0.0049$ ).

We performed Mendelian randomization analysis, instrumented by the SGLT1 haplotype, of 2-h glucose values with cardiometabolic outcomes to estimate the potential effect of pharmacological SGLT1 inhibition on disease phenotypes. A decrease of 20 mg/dl in 2-h glucose levels, instrumented by the SGLT1 haplotype, was associated with lower odds of prevalent obesity (OR: 0.43; 95% CI: 0.23 to 0.63) after adjustment for age, sex, and principal components (Table 4). In long-term outcomes, each decrease of 20 mg/dl in 2-h glucose levels corresponded to a reduced incidence of DM (HR: 0.58; 95% CI: 0.35 to 0.81), HF (HR: 0.53; 95% CI: 0.24 to 0.83), and death (HR: 0.66; 95% CI: 0.42 to 0.90) after adjustment for age, sex, and principal components.

**DISCUSSION**

In European-American subjects and in a separate replication sample of African-American subjects, individuals with NS mutations in SGLT1 had a lower risk of IGT and obesity despite equivalent estimated intake of total calories, sodium, and sugars at baseline, and that this outcome was primarily driven by the N51S/A411T/H615Q haplotype (Central Illustration). We further found that individuals with this haplotype had a lower incidence of DM, initiation of DM therapies, death, and HF. These data suggest that genetic variations in this gene influence the risk of metabolic disease in relation to carbohydrate intake and that selective inhibitors of SGLT1 may be useful in prevention by reducing the burden of metabolic disease and its cardiovascular disease consequences.

**TABLE 4 Mendelian Randomization Analysis of 2-h Glucose Lowering With Cardiometabolic Outcomes in Participants in the ARIC Cohort, Instrumented by the Asn51Ser/Ala411Thr/His615Gln SGLT1 Haplotype**

	OR or HR (95% CI) per 20-mg/dl Lower 2-h Glucose
Prevalent obesity	0.43 (0.23-0.63)
Incident diabetes	0.58 (0.35-0.81)
Incident heart failure	0.53 (0.24-0.83)
Death	0.66 (0.42-0.90)

HR = hazard ratio; other abbreviations as in Tables 1 and 2.



There are several lines of evidence which suggest that the N51S/A411T/H615Q haplotype is likely to be functional. The N51S, A411T, and H615Q variants have been expressed in oocytes in a previous study and were found to reduce uptake of glucose by 70% to 80% compared with controls, suggesting that these variants, in isolation, have slightly reduced function (1). Adding further support to the in vivo studies, Combined Annotation Dependent Depletion scores (18), a measure of pathogenicity, of all 3 variants are high; these findings suggest that the altered amino acid sequences are likely to have functional consequence. Also similar to the in vivo findings, in our work, we observed the strongest association of this haplotype with reduced plasma glucose levels after oral glucose exposure in 3 independent populations, suggesting lower intestinal glucose uptake in haplotype carriers. Of interest, this haplotype includes 3 mutations in *SGLT1*, which may have originated from a single founder. Data from 1,000 Genomes shows that the highest frequency of the haplotype is carried in participants from England and Scotland (12%), followed by those of Indo-European ancestry (between 2% and 7%), South American ancestry (approximately 1% to 2%), and lowest in those with African heritage (0.008%). In a study of the evolutionary history of genes encoding brush-border proteins involved in carbohydrate digestion/absorption, the *SGLT1* A441T and H615Q variants were both detected as positively selected sites in interspecies analysis, with A441T being a modern-human-specific site (19). These data support either a functional role for these haplotype variants or suggest that they are in strong linkage disequilibrium with a functional variant. In analyses of a separate population-based sample comprising individuals of European and specifically Finnish descent, we observed similarly significant findings for postprandial glucose levels and IGT.

To date, there have been no studies, to our knowledge, comprehensively evaluating genetic variation in *SGLT1* with disease in a general population-based cohort of any ethnic/racial composition. Previous research has focused on identifying causal mutations in *SGLT1* for GGM. This research has established that mutations which result in complete loss of function of *SGLT1* lead to the extreme phenotype of GGM: severe neonatal diarrhea causing death from dehydration unless glucose and galactose are removed from the diet. Similar to the presentation in humans, *Sglt1*<sup>-/-</sup> mice develop GGM but are healthy when given a diet absent of glucose and galactose (20,21). When fed a Western-style diet, *Sglt1*<sup>-/-</sup> mice display improved OGTT (20,21). Support

of the critical role of SGLT1 in maintaining body weight comes from RS1 knockout (RS1<sup>[-/-]</sup>) mice. In the absence of RS1, SGLT1 protein is overexpressed 7-fold, resulting in obesity, 30% increased body weight, and 80% increased total body fat compared with that of adult, wild-type mice (22). Although complete loss of function of the protein causes GGM, we would expect that mutations that cause even a subtle change in function in the SGLT1 protein that decreases absorption of intestinal glucose could affect an individual's propensity to develop obesity and thereby reduce risk for DM. True caloric consumption (calories absorbed) would not necessarily reflect the number of calories that have been eaten, and very small changes to the percentage of total glucose eaten/total glucose absorbed could explain a protection or susceptibility to obesity. Adding further support that *SGLT1* is important in determining postprandial glucose levels in human populations, a genome-wide association study of 1,5-anhydroglucitol levels (a biomarker of hyperglycemic excursions) identified significant linkage to *SGLT1* in 2 independent European-American populations (23).

Inhibition of SGLT1 may also have secondary effects that could account for some of the observations of the present study. In studies of humans and model organisms, inhibiting SGLT1 has shown that decreased glucose uptake in the small intestine results in increased luminal glucose in the more distal gut and colon, stimulating a sustained increase in circulating glucagon-like peptide (GLP)-1 and peptide YY from L cells (24-26). This finding may be mediated by bacterial fermentation of luminal glucose to short-chain-fatty-acids that trigger GLP-1 secretion (25,27), leading to beneficial effects such as decreased appetite and improved cardiac function (28,29). Notably, GLP-1 and peptide YY are increased with SGLT1 but not SGLT2-specific inhibition (25). In addition, in our study, lowering of postprandial glucose levels via SGLT1 was associated with protection from HF. In murine models, cardiac knockdown of SGLT1 in PRKAG2 cardiomyopathy attenuated disease expression, suggesting a role of SGLT1 in disease pathogenesis (30). Consistent with this finding, transgenic overexpression of cardiac SGLT1 was associated with myocardial hypertrophy and left ventricular dysfunction that was reversible by SGLT1 suppression. In another study, human cardiac fibroblasts exposed to high glucose levels increased expression of proteins involved in cardiac fibrosis (i.e., matrix metalloproteinase-2) that was reversed by phlorizin (a dual SGLT1 and SGLT2 inhibitor) but not by dapagliflozin (an SGLT2 inhibitor) (31). In addition to our data, these studies

provide support for the role of SGLT1 as a cardiac sodium/glucose transporter that may be involved in cardiomyopathy.

Marketed SGLT2 inhibitors for DM are a relatively new class of drugs approved by the U.S. Food and Drug Administration that vary in their selectivity for the primarily renally expressed SGLT2, relative to the primarily intestinally expressed SGLT1 (32). In addition to pharmacologically inhibiting renal glucose reabsorption, SGLT2 inhibitors have shown the benefits of decreased body weight and blood pressure, and reduced mortality, cardiovascular events, and hospitalization for incident HF, in 2 recently published trials (EMPA-REG [Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients] and CANVAS [Canagliflozin Cardiovascular Assessment Study]) (33,34). Unwanted side effects of SGLT2 inhibition include a higher likelihood of developing genital and urinary tract infections (due to urinary excretion of glucose), osmotic diuresis, and euglycemic ketoacidosis, all of which would be expected to be diminished with increased SGLT1 > SGLT2 inhibition. On a population level, the data presented here indicate that more selective SGLT1 inhibition may be of benefit in attenuating the development of metabolic diseases, suggesting overall cardioprotection. Some of these effects may be mediated through SGLT1-specific mechanisms such as alteration of the microbiome and increased incretin secretion, as described earlier. Although data on SGLT1-specific inhibitors are lacking, initial data from Phase II and III clinical trials of a dual SGLT1/SGLT2 inhibitor is consistent with our findings, with an effect size that was similar to the estimated effect size in this Mendelian randomization analysis (35,36). Our findings further suggest that there may be long-term, protective effects of lowering intestinal glucose absorption via SGLT1 inhibition on cardiometabolic outcomes.

**STUDY LIMITATIONS.** We did not extensively assess the relationship of *SGLT1* mutants in other population studies; however, the ARIC is composed of participants from 4 distinct communities, and we have replicated our findings in 2 diverse racial groups. The association of the N51S/A411T/H615Q haplotype with reduced DM, mortality, and HF should be considered hypothesis generating and must be tested in additional prospective large-sized cohorts with similarly longer term outcomes. Given the putative role of *SGLT1* in mediating diet-induced metabolic risk, mutation-related effects on outcomes may vary based on chronic dietary variation within or between populations; thus, possible nutrient intake interactions

warrant further investigation in cohorts with detailed dietary data in addition to prospective outcomes data.

## CONCLUSIONS

The SGLT1 N51S/A411T/H615Q haplotype was associated with protection from postprandial hyperglycemia and obesity in European- and African-American subjects from 4 U.S. communities and 2 European cohorts from Finland. These data provide support that reduction of postprandial glucose levels via SGLT1 inhibition may be associated with reduced incidence of DM, HF, and/or mortality in certain populations at risk. These data argue for further research into the role of natural variation in *SGLT1* in metabolic disease and suggest that more selective ways to inhibit SGLT1 may lead to therapies that reduce the deleterious effects of Western-style diets.

**ACKNOWLEDGMENTS** The authors thank the staff and participants of the ARIC study for their important contributions, and CSC-IT Center for Science, Finland, for providing computational resources for the FINRISK study.

**ADDRESS FOR CORRESPONDENCE:** Dr. Scott D. Solomon, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115. E-mail: [ssolomon@rics.bwh.harvard.edu](mailto:ssolomon@rics.bwh.harvard.edu). Twitter: [@BrighamWomens](https://twitter.com/BrighamWomens).

## PERSPECTIVES

### COMPETENCY IN MEDICAL KNOWLEDGE:

SGLT1 absorbs glucose from the intestine, while both SGLT2 and SGLT1 are involved in renal reabsorption. Genetic mutations associated with loss of SGLT1 function are associated with lower post-prandial glucose levels and avoidance of obesity.

### COMPETENCY IN PATIENT CARE AND

**PROCEDURAL SKILLS:** SGLT2 inhibitors increase urinary glucose excretion, reduce body weight, and lower mortality and hospitalization for heart failure. Potential adverse effects include urogenital infections and euglycemic ketoacidosis.

**TRANSLATIONAL OUTLOOK:** Additional studies are needed to determine whether drugs that target SGLT1 could reduce the incidence of diabetes and heart failure and improve longevity in the general population.

## REFERENCES

- Martin MG, Turk E, Lostao MP, Kerner C, Wright EM. Defects in Na<sup>+</sup>/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption. *Nat Genet* 1996;12:216-20.
- Turk E, Zabel B, Mundlos S, Dyer J, Wright EM. Glucose/galactose malabsorption caused by a defect in the Na<sup>+</sup>/glucose cotransporter. *Nature* 1991;350:354-6.
- Lam JT, Martin MG, Turk E, et al. Missense mutations in SGLT1 cause glucose-galactose malabsorption by trafficking defects. *Biochim Biophys Acta* 1999;1453:297-303.
- The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. *Am J Epidemiol* 1989;129:687-702.
- Hu FB, Rimm E, Smith-Warner SA, et al. Reproducibility and validity of dietary patterns assessed with a food-frequency questionnaire. *Am J Clin Nutr* 1999;69:243-9.
- White AD, Folsom AR, Chambless LE, et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. *J Clin Epidemiol* 1996;49:223-33.
- Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. *N Engl J Med* 2010;362:800-11.
- Rosamond WD, Chang PP, Baggett C, et al. Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria. *Circ Heart Fail* 2012;5:152-9.
- Bainbridge MN, Wang M, Wu Y, et al. Targeted enrichment beyond the consensus coding DNA sequence exome reveals exons with higher variant densities. *Genome Biol* 2011;12:R68.
- Challis D, Yu J, Evani US, et al. An integrative variant analysis suite for whole exome next-generation sequencing data. *BMC Bioinformatics* 2012;13:8.
- Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 2009;25:1754-60.
- DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet* 2011;43:491-8.
- Danecek P, Auton A, Abecasis G, et al. The variant call format and VCFtools. *Bioinformatics* 2011;27:2156-8.
- Borodulin K, Tolonen H, Jousilahti P, et al. Cohort profile: the national FINRISK Study. *Int J Epidemiol* 2018;47:6961.
- Borodulin K, Vartiainen E, Peltonen M, et al. Forty-year trends in cardiovascular risk factors in Finland. *Eur J Public Health* 2015;25:539-46.
- Konttinen H, Mannisto S, Sarlio-Lahteenkorva S, Silventoinen K, Haukkala A. Emotional eating, depressive symptoms and self-reported food consumption. A population-based study. *Appetite* 2010;54:473-9.
- Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet* 2006;38:904-9.
- Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet* 2014;46:310-5.
- Pontremoli C, Mozzi A, Forni D, et al. Natural selection at the brush-border: adaptations to carbohydrate diets in humans and other mammals. *Genome Biol Evol* 2015;7:2569-84.
- Gorboulev V, Schurmann A, Vallon V, et al. Na<sup>(+)</sup>-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. *Diabetes* 2012;61:187-96.
- Powell DR, DaCosta CM, Gay J, et al. Improved glycemic control in mice lacking SglT1 and SglT2. *Am J Physiol Endocrinol Metab* 2013;304:E117-30.
- Osswald C, Baumgarten K, Stumpel F, et al. Mice without the regulator gene Rsc1A1 exhibit increased Na<sup>+</sup>-D-glucose cotransport in small intestine and develop obesity. *Mol Cell Biol* 2005;25:78-87.
- Li M, Maruthur NM, Loomis SJ, et al. Genome-wide association study of 1,5-anhydroglucitol identifies novel genetic loci linked to glucose metabolism. *Sci Rep* 2017;7:2812.
- Dobbins RL, Greenway FL, Chen L, et al. Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. *Am J Physiol Gastrointest Liver Physiol* 2015;308:G946-54.
- Powell DR, Smith M, Greer J, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. *J Pharmacol Exp Ther* 2013;345:250-9.
- Shibazaki T, Tomae M, Ishikawa-Takemura Y, et al. KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. *J Pharmacol Exp Ther* 2012;342:288-96.
- Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. *Diabetes* 2012;61:364-71.
- Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. *J Clin Invest* 1998;101:515-20.
- Takahashi A, Ihara M, Yamazaki S, Asanuma H, Asakura M, Kitakaze M. Impact of either GLP-1 agonists or DPP-4 inhibitors on pathophysiology of heart failure. *Int Heart J* 2015;56:372-6.
- Ramratnam M, Sharma RK, D'Auria S, et al. Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice. *J Am Heart Assoc* 2014;3.
- Meng L, Uzui H, Guo H, Tada H. Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts. *Mol Med Rep* 2018;17:6887-92.
- Lehmann A, Hornby PJ. Intestinal SGLT1 in metabolic health and disease. *Am J Physiol Gastrointest Liver Physiol* 2016;310:G887-98.
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med* 2015;373:2117-28.
- Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med* 2017;377:644-57.
- Zambrowicz B, Ogbaa I, Frazier K, et al. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects. *Clin Ther* 2013;35:1162-73.e8.
- Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. *N Engl J Med* 2017;377:2337-48.

**KEY WORDS** glucose tolerance, Mendelian randomization, SGLT1

**APPENDIX** For supplemental tables and a figure, please see the online version of this paper.